Dexmedetomidine RPH Pharma: Uses, Dosage & Side Effects

What Is Dexmedetomidine RPH Pharma and What Is It Used For?

Dexmedetomidine RPH Pharma contains the active substance dexmedetomidine hydrochloride, which is the pharmacologically active dextro-enantiomer of medetomidine. As a highly selective alpha-2 adrenoceptor agonist, dexmedetomidine possesses a unique combination of sedative, analgesic, and anxiolytic properties that distinguishes it from all other classes of sedative agents used in intensive care medicine. The alpha-2 to alpha-1 selectivity ratio of dexmedetomidine is approximately 1,620:1, making it eight times more selective for alpha-2 receptors than clonidine, which was the first clinically available alpha-2 agonist.

The sedation produced by dexmedetomidine is fundamentally different from that achieved with propofol, benzodiazepines, or barbiturates. While traditional sedatives act primarily through modulation of gamma-aminobutyric acid (GABA) receptors to produce dose-dependent central nervous system depression that can progress from sedation to general anaesthesia and ultimately respiratory arrest, dexmedetomidine acts on alpha-2 adrenoceptors in the locus coeruleus of the brainstem. The locus coeruleus is a critical nucleus in the regulation of wakefulness and arousal, and its inhibition by dexmedetomidine produces a state that electroencephalographically and behaviourally resembles natural non-rapid eye movement (NREM) stage 2 sleep. This means that patients sedated with dexmedetomidine can transition between sleep and wakefulness in response to stimulation, maintaining the ability to communicate and cooperate with clinical assessments when aroused, while returning to restful sedation when left undisturbed.

This property of “cooperative sedation” or “arousable sedation” is clinically invaluable in the ICU setting. It allows healthcare professionals to perform neurological assessments, interact with patients regarding pain management and comfort, and facilitate early mobilization—all of which are associated with improved outcomes in critically ill patients. The sedation depth achievable with dexmedetomidine corresponds to a Richmond Agitation-Sedation Scale (RASS) score of 0 to −3, which represents light-to-moderate sedation. Dexmedetomidine is not appropriate when deep sedation (RASS −4 to −5) or general anaesthesia is required.

A defining advantage of dexmedetomidine over GABA-ergic sedatives is its minimal effect on respiratory drive. At therapeutic doses, dexmedetomidine does not produce clinically significant respiratory depression. The respiratory rate and tidal volume are generally preserved, and the ventilatory response to carbon dioxide remains intact. This makes dexmedetomidine particularly well-suited for several clinical scenarios: sedation during weaning from mechanical ventilation, sedation of non-intubated patients who require spontaneous ventilation, and procedural sedation where preservation of airway reflexes is desirable. However, it should be noted that upper airway obstruction can occur with deeper levels of sedation, particularly in patients with pre-existing obstructive sleep apnoea or anatomical airway abnormalities.

Dexmedetomidine RPH Pharma is approved for two main indications in adult patients:

• ICU sedation: Sedation of adult ICU patients requiring a sedation level not deeper than arousal in response to verbal stimulation (corresponding to RASS 0 to −3). This includes both initially intubated and mechanically ventilated patients and patients who are non-intubated before or after extubation. Dexmedetomidine can be used as the sole sedative agent for light-to-moderate sedation or as an adjunct to other sedatives when deeper levels of sedation are needed intermittently.
• Procedural sedation (non-ICU): Sedation of non-intubated adult patients prior to and/or during diagnostic or surgical procedures requiring sedation, also known as monitored anaesthesia care. This includes procedures such as awake fibreoptic intubation, cataract surgery under regional anaesthesia, diagnostic imaging in claustrophobic patients, and minor surgical procedures where patient cooperation is beneficial.

The clinical evidence supporting dexmedetomidine in ICU sedation comes from several landmark randomized controlled trials. The MIDEX trial (Dexmedetomidine versus Midazolam for Long-Term ICU Sedation) demonstrated that dexmedetomidine was non-inferior to midazolam for maintaining adequate sedation, while significantly reducing the duration of mechanical ventilation and improving patients’ ability to communicate their pain. The PRODEX trial (Dexmedetomidine versus Propofol for Long-Term ICU Sedation) showed similar non-inferiority to propofol, with dexmedetomidine-treated patients requiring less rescue medication (fentanyl and propofol) and having shorter times to extubation. The SPICE III trial, one of the largest sedation trials in ICU medicine, evaluated dexmedetomidine-based sedation against usual care in over 4,000 mechanically ventilated adults and demonstrated comparable 90-day mortality with a reduction in delirium and coma duration.

Beyond its primary sedative effects, dexmedetomidine possesses modest analgesic properties. It reduces pain transmission at the level of the spinal cord dorsal horn by activating alpha-2 receptors on primary afferent neurons, reducing the release of substance P and other neurotransmitters involved in pain signaling. While the analgesic effect is generally insufficient as sole analgesia for major surgery or severe pain, it can reduce opioid requirements by 30–50% when used as an adjunct, which in turn helps to minimize opioid-related side effects such as nausea, ileus, respiratory depression, and the development of tolerance and hyperalgesia.

What Should You Know Before Taking Dexmedetomidine RPH Pharma?

Contraindications

Dexmedetomidine RPH Pharma is contraindicated in patients with known hypersensitivity to dexmedetomidine hydrochloride or to any of the excipients in the formulation. The key clinical contraindications reflect the cardiovascular effects of alpha-2 adrenergic agonism and include the following scenarios:

• Advanced heart block: Second-degree (Mobitz type II) or third-degree atrioventricular (AV) block in the absence of a functioning permanent pacemaker. Dexmedetomidine enhances vagal tone and reduces sympathetic outflow, which can exacerbate conduction abnormalities and lead to haemodynamically significant bradycardia or asystole.
• Uncontrolled hypotension: Patients with severe, uncontrolled hypotension are at risk of further haemodynamic compromise due to the sympatholytic effects of dexmedetomidine, which reduce both heart rate and systemic vascular resistance.
• Acute cerebrovascular conditions: Patients with acute stroke or other acute cerebrovascular events may be at increased risk due to alterations in cerebral blood flow and perfusion pressure associated with the hypotensive effects of dexmedetomidine.

Warnings and Precautions

Before and during administration of dexmedetomidine, clinicians should be aware of the following precautions:

• Cardiovascular effects: Hypotension and bradycardia are the most common haemodynamic effects. In healthy volunteers and ICU patients, heart rate reductions of 20–30% from baseline are typical. Blood pressure may decrease or, transiently, increase. A biphasic blood pressure response can occur: an initial hypertensive phase during loading doses (caused by peripheral alpha-2B receptor-mediated vasoconstriction) followed by sustained hypotension during maintenance infusion (caused by central sympatholysis). Patients with significant heart failure (NYHA class III–IV), severe bradycardia (<50 bpm), or those on beta-blockers, calcium channel blockers, or other negative chronotropes are at particular risk and require careful dose titration.
• Hepatic impairment: Dexmedetomidine is extensively metabolized by the liver. In patients with hepatic impairment, clearance is reduced, and the elimination half-life is prolonged. Dose reduction should be considered, and the rate of infusion should be titrated according to clinical response. Close monitoring of liver function is advisable during prolonged infusions.
• Renal impairment: Although dexmedetomidine is primarily eliminated as inactive metabolites in the urine, no dose adjustment is generally required in patients with renal impairment. However, the haemodynamic effects (hypotension) may be more pronounced in patients with chronic kidney disease due to co-existing cardiovascular pathology and altered fluid balance.
• Diabetes mellitus and autonomic neuropathy: Patients with diabetes mellitus, especially those with autonomic neuropathy, may have an impaired compensatory response to the hypotensive effects of dexmedetomidine and may be more susceptible to bradycardia and hypotension.
• Withdrawal effects: After prolonged infusion (typically >24 hours), abrupt discontinuation may occasionally result in withdrawal-like symptoms including nervousness, agitation, headache, and rebound hypertension, analogous to clonidine withdrawal. Gradual tapering of the infusion rate is recommended when discontinuing dexmedetomidine after extended use.

Pregnancy and Breastfeeding

There are limited data on the use of dexmedetomidine in pregnant women. Animal studies have shown adverse effects on the foetus at high doses, including decreased foetal body weight and delayed ossification. Dexmedetomidine crosses the placenta and may cause foetal bradycardia. Dexmedetomidine RPH Pharma should not be used during pregnancy unless the clinical condition of the woman requires treatment and no safer alternative is available. The potential benefits must be carefully weighed against the potential risks to the foetus.

Dexmedetomidine is excreted in human breast milk. Studies in lactating women have demonstrated that dexmedetomidine appears in breast milk with a relative infant dose estimated at approximately 0.04–0.09% of the maternal dose. Given the low bioavailability of dexmedetomidine via oral administration, the risk to the breastfed infant is considered low. However, as a precaution, breastfeeding should be temporarily suspended during treatment with dexmedetomidine and for 24 hours after the last dose, and expressed milk should be discarded during this period.

Children and Adolescents

Dexmedetomidine RPH Pharma is not recommended for use in children and adolescents under 18 years of age due to insufficient data on safety and efficacy. While dexmedetomidine has been used off-label in paediatric intensive care and procedural sedation settings, and some observational studies suggest a favourable safety profile, formal regulatory approval for paediatric use has not been granted. Paediatric use should be at the discretion of the treating specialist, with careful dose adjustment and monitoring. The pharmacokinetic profile in neonates and young infants differs significantly from adults, with reduced hepatic clearance and a prolonged elimination half-life.

Driving and Operating Machinery

Dexmedetomidine has a major influence on the ability to drive and use machines. Patients should be advised not to drive, operate complex machinery, or engage in potentially dangerous activities for 24 hours after receiving dexmedetomidine, as residual sedative effects and impaired cognitive and psychomotor function may persist after the infusion is stopped. This is particularly relevant for patients receiving dexmedetomidine for procedural sedation who are discharged on the same day.

How Does Dexmedetomidine RPH Pharma Interact with Other Drugs?

Dexmedetomidine is metabolized primarily by hepatic enzymes, including direct glucuronidation (UGT1A4, UGT2B10) and cytochrome P450 2A6 (CYP2A6)-mediated oxidation. While no specific pharmacokinetic drug-drug interaction studies with CYP2A6 inhibitors or inducers have been conducted, the primary clinical interactions of dexmedetomidine are pharmacodynamic in nature, resulting from additive or synergistic effects with other medications that affect the central nervous system or cardiovascular system.

The following table summarizes the most clinically significant drug interactions with dexmedetomidine:

The interaction between dexmedetomidine and anaesthetic agents is one of the most clinically important. Studies have consistently demonstrated that dexmedetomidine reduces the minimum alveolar concentration (MAC) of volatile anaesthetics (sevoflurane, isoflurane, desflurane) by approximately 25–50%, and reduces propofol requirements for induction and maintenance of anaesthesia by a similar magnitude. This is thought to be mediated by the central sympatholytic and sedative effects of alpha-2 receptor activation in the brainstem, which reduces overall arousal and enhances the hypnotic effects of GABA-ergic anaesthetics.

The combination of dexmedetomidine with opioids is commonly encountered in ICU practice and warrants particular attention. While dexmedetomidine and opioids have complementary mechanisms of analgesia (alpha-2 agonism at the spinal cord level and mu-opioid receptor activation, respectively), their co-administration can produce enhanced sedation and, at higher doses, increased risk of respiratory depression. Clinical trials have demonstrated that dexmedetomidine-based sedation regimens can reduce cumulative opioid consumption by 30–50% compared with midazolam or propofol-based regimens, which is a significant clinical benefit in terms of reducing opioid-related adverse effects.

Regarding pharmacokinetic interactions, dexmedetomidine is not a significant inhibitor or inducer of major cytochrome P450 enzymes at clinically relevant concentrations. However, potent CYP2A6 inhibitors (such as methoxsalen) may theoretically increase dexmedetomidine plasma concentrations, and potent CYP2A6 inducers (such as rifampicin) may decrease them, although these interactions have not been formally studied and are unlikely to be clinically significant given the typical ICU context of use.

What Is the Correct Dosage of Dexmedetomidine RPH Pharma?

Dexmedetomidine RPH Pharma must be diluted before intravenous administration. The concentrate (100 micrograms/ml) is typically diluted in sodium chloride 0.9% (normal saline) to a final concentration of 4 micrograms/ml. This is achieved by adding 2 ml of concentrate (200 micrograms) to 48 ml of sodium chloride 0.9%, yielding a 50 ml solution at 4 micrograms/ml. Glucose 5% may also be used as a diluent. The diluted solution should be gently mixed and used within 24 hours. It must be administered using a controlled infusion device (syringe pump or volumetric pump).

Adults – ICU Sedation

For ICU sedation, the optimal approach is to titrate the infusion rate to the target sedation level, typically a RASS score of 0 to −3 (light-to-moderate sedation). The initial maintenance rate of 0.7 micrograms/kg/hour is a reasonable starting point for most patients. The infusion rate should be adjusted in increments of 0.1–0.2 micrograms/kg/hour at intervals of no less than 30 minutes, based on regular sedation assessments. If adequate sedation is not achieved at the maximum recommended dose of 1.4 micrograms/kg/hour, alternative or supplementary sedation should be considered. The use of a loading dose is optional and may be associated with an increased incidence of haemodynamic adverse effects (bradycardia and transient hypertension). Many clinicians choose to omit the loading dose, particularly in patients who are haemodynamically compromised or already receiving other sedative agents.

Adults – Procedural Sedation

For procedural sedation, the loading infusion is generally recommended to achieve an adequate sedation level before the start of the procedure. The rate of the maintenance infusion is then adjusted to maintain the desired level of sedation throughout the procedure. Local or regional anaesthesia should be administered before the procedure when appropriate, as dexmedetomidine alone may not provide sufficient analgesia for painful procedures. Supplementary doses of other sedatives or analgesics (such as small boluses of midazolam, propofol, or opioids) may be required during the procedure to manage acute episodes of discomfort or anxiety.

Elderly Patients

Elderly patients (aged 65 years and above) may exhibit enhanced sensitivity to the sedative and cardiovascular effects of dexmedetomidine. A reduced initial loading dose and slower titration of the maintenance infusion are recommended. Many clinicians use a loading dose of 0.5 micrograms/kg (rather than 1.0 micrograms/kg) and initiate the maintenance infusion at the lower end of the dosing range (0.2–0.5 micrograms/kg/hour). The need for dose reduction is primarily due to age-related changes in cardiovascular physiology (reduced baroreflex sensitivity, decreased cardiac output reserve) and potentially reduced hepatic clearance.

Hepatic Impairment

Dexmedetomidine is extensively metabolized in the liver, and its clearance is reduced in patients with hepatic impairment. In moderate hepatic impairment (Child-Pugh B), clearance may be reduced by approximately 50%, leading to higher plasma concentrations and prolonged effects. In severe hepatic impairment (Child-Pugh C), the reduction may be even more pronounced. Dose reduction is recommended: consider initiating the maintenance infusion at the lower end of the dosing range and titrating slowly. Close monitoring of sedation depth and cardiovascular parameters is essential.

Missed Dose

As dexmedetomidine is administered as a continuous intravenous infusion in a monitored healthcare setting, the concept of a missed dose does not apply in the conventional sense. If the infusion is inadvertently interrupted, it should be restarted at the previously effective rate and retitrated as needed. Brief interruptions in the infusion are unlikely to cause clinically significant rebound effects, but prolonged interruptions after extended use may be associated with agitation and sympathetic rebound.

Overdose

Overdose with dexmedetomidine may manifest as an exaggeration of its pharmacological effects: profound bradycardia, severe hypotension, excessive sedation, and, in extreme cases, cardiac arrest. Management is primarily supportive and symptomatic. For clinically significant bradycardia, atropine or glycopyrrolate can be administered; for severe or refractory bradycardia, temporary cardiac pacing may be necessary. Hypotension should be managed with intravenous fluid resuscitation and, if necessary, vasopressor support (e.g., phenylephrine, norepinephrine). The elimination half-life of dexmedetomidine is approximately 2 hours, so the effects of overdose will generally resolve within a few hours of stopping the infusion, provided supportive care is maintained.

What Are the Side Effects of Dexmedetomidine RPH Pharma?

As with all medicines, dexmedetomidine can cause side effects, although not everyone will experience them. The side effect profile of dexmedetomidine is predominantly cardiovascular, reflecting its pharmacological action on alpha-2 adrenergic receptors. In clinical trials, the overall incidence of adverse events was similar between dexmedetomidine and active comparators (midazolam and propofol), but the nature of the events differed: dexmedetomidine was associated with more bradycardia and hypotension, while comparators were associated with more respiratory depression and deeper-than-intended sedation.

The following side effects have been reported during clinical trials and post-marketing surveillance, categorized by frequency:

The cardiovascular side effects of dexmedetomidine merit detailed discussion, as they are the most clinically significant and most commonly encountered. Hypotension occurs in approximately one-quarter to over half of patients, depending on the patient population, concurrent medications, and dosing regimen. The hypotension is primarily caused by centrally mediated reduction in sympathetic outflow, leading to decreased heart rate, cardiac output, and systemic vascular resistance. It is typically mild to moderate and often does not require intervention beyond dose adjustment. In the MIDEX and PRODEX trials, the incidence of treatment-requiring hypotension was similar between dexmedetomidine and comparators.

Bradycardia is the second most common cardiovascular effect and results from both reduced sympathetic tone and enhanced vagal activity. Heart rate reductions of 20–30% from baseline are typical. In most cases, the bradycardia is well-tolerated and does not require intervention. However, severe bradycardia (heart rate <40 bpm) or haemodynamically significant bradycardia can occur, particularly in patients with pre-existing conduction abnormalities, those on concurrent negative chronotropic agents (beta-blockers, digoxin), or those receiving rapid loading doses. Treatment options include atropine (0.5–1.0 mg IV), glycopyrrolate (0.2–0.4 mg IV), dose reduction, or temporary cessation of the infusion.

The hypertensive response observed during loading doses is caused by activation of peripheral (postsynaptic) alpha-2B adrenoceptors on vascular smooth muscle, leading to direct vasoconstriction. This effect is typically transient (lasting 5–10 minutes) and is followed by the sustained hypotensive effect of central sympatholysis as dexmedetomidine equilibrates in the central nervous system. The hypertensive response can be minimised by administering the loading dose slowly (over 10–20 minutes) or by omitting the loading dose altogether.

Dry mouth (xerostomia) is a characteristic pharmacological effect of alpha-2 agonists, resulting from reduced salivary secretion via inhibition of parasympathetic and sympathetic stimulation of salivary glands. While generally a minor inconvenience, it can affect patient comfort and oral care in the ICU setting.

How Should You Store Dexmedetomidine RPH Pharma?

Proper storage of Dexmedetomidine RPH Pharma is essential to maintain the quality and safety of the medication. As a concentrate for solution for infusion, the product must be handled according to standard pharmaceutical practices for injectable preparations.

• Unopened vials: Store below 25°C (77°F). Do not freeze. Keep the vials in the outer carton to protect from light. The concentrate does not require refrigeration for storage, but should be protected from excessive heat.
• After dilution: Chemical and physical in-use stability of the diluted solution has been demonstrated for up to 24 hours at 25°C. From a microbiological perspective, the diluted solution should be used immediately after preparation. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not exceed 24 hours at 2–8°C, unless dilution has taken place in controlled and validated aseptic conditions.
• Do not freeze: The concentrate and diluted solution should not be frozen, as crystallisation or changes in potency may occur.
• Visual inspection: Before administration, visually inspect the solution for particulate matter, discolouration, and container integrity. The concentrate should be a clear, colourless solution. Do not use if the solution is cloudy, discoloured, or contains visible particles, or if the container appears damaged.
• Single use: Dexmedetomidine RPH Pharma vials are for single use only. Any unused product or waste material should be disposed of in accordance with local requirements for the disposal of pharmaceutical waste.
• Keep out of reach of children: Store the medication in a secure location within the hospital pharmacy or clinical area, out of the sight and reach of children.
• Expiration date: Do not use the medication after the expiration date printed on the vial label and carton after “EXP.” The expiration date refers to the last day of the stated month.

The diluted dexmedetomidine solution is compatible with sodium chloride 0.9%, glucose 5%, Ringer’s lactate solution, and mannitol 20%. It should be administered through a dedicated intravenous line or the dedicated lumen of a multi-lumen catheter. Do not mix dexmedetomidine with other drugs in the same syringe or infusion container, and do not add it to blood or blood products.

What Does Dexmedetomidine RPH Pharma Contain?

Understanding the composition of Dexmedetomidine RPH Pharma is important for healthcare professionals, particularly when considering potential incompatibilities and allergies.

Active Ingredient

The active substance is dexmedetomidine, present as dexmedetomidine hydrochloride. Each ml of concentrate for solution for infusion contains 100 micrograms of dexmedetomidine (equivalent to 118 micrograms of dexmedetomidine hydrochloride per ml). Dexmedetomidine is the pharmacologically active S-enantiomer of medetomidine and is classified as a highly selective alpha-2 adrenoceptor agonist with sedative, analgesic, and sympatholytic properties.

Inactive Ingredients (Excipients)

Appearance and Pack Sizes

Dexmedetomidine RPH Pharma is a clear, colourless concentrate for solution for infusion supplied in glass vials. It is available in 2 ml vials (containing 200 micrograms of dexmedetomidine), 4 ml vials (containing 400 micrograms), and 10 ml vials (containing 1,000 micrograms). Each vial is for single use only. The product may be supplied in packs of 1, 4, 5, or 25 vials. Not all pack sizes may be marketed in every country.

Sodium Content

Dexmedetomidine RPH Pharma contains sodium chloride as an excipient. Each 2 ml vial contains approximately 0.354 mmol (8.13 mg) of sodium per vial, which is essentially sodium-free. However, when the concentrate is diluted in 48 ml of sodium chloride 0.9% for infusion, the sodium content of the final solution will be predominantly from the diluent. This should be considered in patients on sodium-restricted diets or those with conditions requiring careful sodium management, such as heart failure or renal impairment.